Brodalumab in psoriasis: evidence to date and clinical potential

Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Foulkes, Amy C, Warren, Richard B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474429/
https://www.ncbi.nlm.nih.gov/pubmed/31024633
http://dx.doi.org/10.7573/dic.212570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474429/
https://www.ncbi.nlm.nih.gov/pubmed/31024633
http://dx.doi.org/10.7573/dic.212570

Ejemplares similares